|
1
|
Rommens JM, Iannuzzi MC, Kerem B, Drumm
ML, Melmer G, Dean M, Rozmahel R, Cole JL, Kennedy D, Hidaka N, et
al: Identification of the cystic fibrosis gene: Chromosome walking
and jumping. Science. 245:1059–1065. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Corradi V, Vergani P and Tieleman DP:
Cystic fibrosis transmembrane conductance regulator (CFTR): Closed
and open state channel models. J Biol Chem. 290:22891–22906. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Elborn JS: Cystic fibrosis. Lancet.
388:2519–2531. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Caputo A, Hinzpeter A, Caci E, Pedemonte
N, Arous N, Di Duca M, Zegarra-Moran O, Fanen P and Galietta LJ:
Mutation-specific potency and efficacy of cystic fibrosis
transmembrane conductance regulator chloride channel potentiators.
J Pharmacol Exp Ther. 330:783–791. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cheng SH, Gregory RJ, Marshall J, Paul S,
Souza DW, White GA, O'Riordan CR and Smith AE: Defective
intracellular transport and processing of CFTR is the molecular
basis of most cystic fibrosis. Cell. 63:827–834. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dalemans W, Barbry P, Champigny G, Jallat
S, Dott K, Dreyer D, Crystal RG, Pavirani A, Lecocq JP and
Lazdunski M: Altered chloride ion channel kinetics associated with
the delta F508 cystic fibrosis mutation. Nature. 354:526–528. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Riordan JR: CFTR function and prospects
for therapy. Annu Rev Biochem. 77:701–726. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pedemonte N and Galietta LJ:
Pharmacological Correctors of Mutant CFTR Mistrafficking. Front
Pharmacol. 3:1752012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nieddu E, Pollarolo B, Mazzei MT, Anzaldi
M, Schenone S, Pedemonte N, Pesce E, Galietta LJ and Mazzei M: The
search for a common structural moiety among selected
pharmacological correctors of the mutant CFTR chloride channel.
Futur Med Chem. 6:1857–1868. 2014. View Article : Google Scholar
|
|
10
|
Wang X, Venable J, LaPointe P, Hutt DM,
Koulov AV, Coppinger J, Gurkan C, Kellner W, Matteson J, Plutner H,
et al: Hsp90 cochaperone Aha1 downregulation rescues misfolding of
CFTR in cystic fibrosis. Cell. 127:803–815. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mu TW, Ong DS, Wang YJ, Balch WE, Yates JR
III, Segatori L and Kelly JW: Chemical and biological approaches
synergize to ameliorate protein-folding diseases. Cell.
134:769–781. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zegarra-Moran O, Monteverde M, Galietta LJ
and Moran O: Functional analysis of mutations in the putative
binding site for cystic fibrosis transmembrane conductance
regulator potentiators. Interaction between activation and
inhibition. J Biol Chem. 282:9098–9104. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sondo E, Tomati V, Caci E, Esposito AI,
Pfeffer U, Pedemonte N and Galietta LJ: Rescue of the mutant CFTR
chloride channel by pharmacological correctors and low temperature
analyzed by gene expression profiling. Am J Physiol Cell Physiol.
301:C872–C885. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Langron E, Simone MI, Delalande CM,
Reymond JL, Selwood DL and Vergani P: Improved fluorescence assays
to measure the defects associated with F508del-CFTR allow
identification of new active compounds. Br J Pharmacol.
174:525–539. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bali V, Lazrak A, Guroji P, Matalon S and
Bebok Z: Mechanistic approaches to improve correction of the most
common disease-causing mutation in cystic fibrosis. PLoS One.
11:e01558822016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Basile A, Pascale M, Franceschelli S,
Nieddu E, Mazzei MT, Fossa P, Turco MC and Mazzei M: Matrine
modulates HSC70 levels and rescues DeltaF508-CFTR. J Cell Physiol.
227:3317–3323. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Verkman A, LJ V Galietta and Guy RK:
Compounds having activity in increasing ion transport by
mutant-cftr and uses thereof. US Patent WO2004110352. Filed July
14, 2004; issued December 23. 2004.
|
|
18
|
Pedemonte N, Diena T, Caci E, Nieddu E,
Mazzei M, Ravazzolo R, Zegarra-Moran O and Galietta LJ:
Antihypertensive 1,4-dihydropyridines as correctors of the cystic
fibrosis transmembrane conductance regulator channel gating defect
caused by cystic fibrosis mutations. Mol Pharmacol. 68:1736–1746.
2005.PubMed/NCBI
|
|
19
|
Cateni F, Zacchigna M, Pedemonte N,
Galietta LJ, Mazzei MT, Fossa P, Giampieri M and Mazzei M:
Synthesis of 4-thiophen-2′-yl-1,4-dihydropyridines as potentiators
of the CFTR chloride channel. Bioorg Med Chem. 17:7894–7903. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Giampieri M, Vanthuyne N, Nieddu E, Mazzei
MT, Anzaldi M, Pedemonte N, Galietta LJ, Roussel C and Mazzei M:
Asymmetric 4-Aryl-1,4-dihydropyridines potentiate mutant cystic
fibrosis transmembraneconductance regulator (CFTR). Chem Med Chem.
7:1799–1807. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Galietta LJ, Haggie PM and Verkman AS:
Green fluorescent protein-based halide indicators with improved
chloride and iodide affinities. FEBS Lett. 499:220–224. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Marengo B, De Ciucis C, Ricciarelli R,
Passalacqua M, Nitti M, Zingg JM, Marinari UM, Pronzato MA and
Domenicotti C: PKCdelta sensitizes neuroblastoma cells to
L-buthionine-sulfoximine and etoposide inducing reactive oxygen
species overproduction and DNA damage. PLoS One. 6:e146612011.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Colla R, Izzotti A, De Ciucis C, Fenoglio
D, Ravera S, Speciale A, Ricciarelli R, Furfaro AL, Pulliero A,
Passalacqua M, et al: Glutathione-mediated antioxidant response and
aerobic metabolism: two crucial factors involved in determining the
multi-drug resistance of high-risk neuroblastoma. Oncotarget.
7:70715–70737. 2016.PubMed/NCBI
|
|
24
|
Galietta LV, Jayaraman S and Verkman AS:
Cell-based assay for high-throughput quantitative screening of CFTR
chloride transport agonists. Am J Physiol Cell Physiol.
281:C1734–C1742. 2001.PubMed/NCBI
|
|
25
|
McAuley DF and Elborn JS: Cystic fibrosis:
Basic science. Paediatr Respir Rev. 1:93–100. 2000.PubMed/NCBI
|
|
26
|
Deeks ED: Lumacaftor/Ivacaftor: A review
in cystic fibrosis. Drugs. 76:1191–1201. 2016. View Article : Google Scholar : PubMed/NCBI
|
